Abbisko Cayman (HKG:2256) recorded a profit of 28.3 million yuan for the year 2024, compared with a loss of 431.6 million yuan in the year-ago period, a Monday filing with the Hong Kong bourse stated.
Earnings per share were 0.04 yuan in the year, while the company had incurred a loss per share of 0.67 yuan in the corresponding period last year.
The drugmaker's revenue rose by 2,544% year over year to 504 million yuan from 19.1 million yuan a year prior.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.